VYNE - VYNE Therapeutics Inc. Stock Price, Fair Value and News

2.48USD-0.05 (-1.98%)Market Closed

Market Summary

USD2.48-0.05

Market Closed

-1.98%

VYNE Stock Price

View Fullscreen

VYNE RSI Chart

VYNE Valuation

Market Cap

35.0M

Price/Earnings (Trailing)

-1.23

Price/Sales (Trailing)

82.47

EV/EBITDA

-0.16

Price/Free Cashflow

-1.38

VYNE Price/Sales (Trailing)

VYNE Profitability

EBT Margin

-6573.70%

Return on Equity

-32.06%

Return on Assets

-29.13%

Free Cashflow Yield

-72.47%

VYNE Fundamentals

VYNE Revenue

Revenue (TTM)

424.0K

Rev. Growth (Yr)

1.2K%

Rev. Growth (Qtr)

-33.33%

VYNE Earnings

Earnings (TTM)

-28.5M

Earnings Growth (Yr)

37.78%

Earnings Growth (Qtr)

6.01%

Breaking Down VYNE Revenue

Last 7 days

0.4%

Last 30 days

-17.9%

Last 90 days

30.5%

Trailing 12 Months

-60.2%

How does VYNE drawdown profile look like?

VYNE Financial Health

Current Ratio

12.73

VYNE Investor Care

Shares Dilution (1Y)

331.92%

Diluted EPS (TTM)

-2.79

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	398.0K	407.0K	354.0K	424.0K
2022	879.0K	710.0K	744.0K	477.0K
2021	16.0M	11.0M	5.9M	931.0K
2020	1.9M	13.6M	16.8M	21.0M
2019	2.8M	2.0M	1.2M	443.0K
2018	4.3M	4.1M	3.8M	3.6M
2017	1.1M	1.6M	2.3M	4.6M
2016	0	0	0	674.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of VYNE Therapeutics Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	stuart iain	sold (taxes)	-483	3.08	-157	chief scientific officer
Apr 01, 2024	harsch mutya	sold (taxes)	-495	3.08	-161	chief legal officer and gc
Apr 01, 2024	zeronda tyler	sold (taxes)	-289	3.08	-94.00	chief financial officer
Apr 01, 2024	domzalski david	sold (taxes)	-3,092	3.08	-1,004	president and ceo
Jan 02, 2024	harsch mutya	sold (taxes)	-367	2.28	-161	chief legal officer and gc
Jan 02, 2024	zeronda tyler	sold (taxes)	-212	2.28	-93.00	chief financial officer
Jan 02, 2024	domzalski david	sold (taxes)	-2,289	2.28	-1,004	president and ceo
Jan 02, 2024	stuart iain	sold (taxes)	-357	2.28	-157	chief scientific officer
Jan 01, 2024	stuart iain	acquired	-	-	62,500	chief scientific officer
Jan 01, 2024	zeronda tyler	acquired	-	-	62,500	chief financial officer

Which funds bought or sold VYNE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 01, 2024	CONCOURSE FINANCIAL GROUP SECURITIES, INC.	sold off	-	-	-	-%
Apr 24, 2024	AlphaCentric Advisors LLC	reduced	-33.4	-190,642	1,366,150	0.82%
Apr 16, 2024	Indiana Trust & Investment Management CO	sold off	-100	-28.00	-	-%
Mar 11, 2024	VANGUARD GROUP INC	added	10.44	-65,850	115,526	-%
Feb 20, 2024	EVENTIDE ASSET MANAGEMENT, LLC	new	-	3,248,800	3,248,800	0.05%
Feb 15, 2024	Palo Alto Investors LP	new	-	1,037,860	1,037,860	0.09%
Feb 15, 2024	Exome Asset Management LLC	new	-	275,173	275,173	0.27%
Feb 14, 2024	Royal Bank of Canada	reduced	-42.37	-6,000	3,000	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-19,481	27,179	-%

Are Funds Buying or Selling VYNE?

Are funds buying VYNE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VYNE

No. of Funds

Unveiling VYNE Therapeutics Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	citadel advisors llc	8.5%	6	SC 13G/A
Feb 02, 2024	soleus capital master fund, l.p.	5.0%	703,868	SC 13G/A
Nov 13, 2023	citadel advisors llc	8.5%	6	SC 13G
Nov 13, 2023	eventide asset management, llc	9.99%	1,394,336	SC 13G
Nov 13, 2023	ai biotechnology llc	19.99%	3,201,980	SC 13D
Nov 13, 2023	cormorant asset management, lp	9.99%	1,394,336	SC 13G
Nov 02, 2023	soleus capital master fund, l.p.	6.4%	890,868	SC 13G
Feb 15, 2022	perceptive advisors llc	4.5%	2,425,604	SC 13G/A
Aug 25, 2021	perceptive advisors llc	9.6%	4,987,887	SC 13G/A
Jul 12, 2021	blackrock inc.	2.0%	1,037,677	SC 13G/A

Recent SEC filings of VYNE Therapeutics Inc.

View All Filings

Date Filed	Form Type	Document
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Apr 03, 2024	4	Insider Trading
Mar 14, 2024	EFFECT	EFFECT
Mar 12, 2024	CORRESP	CORRESP
Mar 06, 2024	UPLOAD	UPLOAD
Mar 01, 2024	S-8	Employee Benefits Plan
Mar 01, 2024	S-3	S-3
Mar 01, 2024	10-K	Annual Report

Peers (Alternatives to VYNE Therapeutics Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.1B	6.8B	21.21%	-3.50%	-8.06	7.03	-64.45%	-224.75%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	19.0B	2.0B	-0.48%	-24.66%	-57.25	9.49	75.20%	68.82%
BMRN	15.9B	2.5B	-3.50%	-10.49%	77.41	6.43	13.74%	186.89%
INCY	11.9B	3.8B	-4.91%	-21.97%	15.99	3.16	8.58%	129.81%
MID-CAP
APLS	5.7B	396.6M	-14.74%	-44.14%	-10.83	14.44	425.83%	18.94%
BBIO	5.2B	107.9M	-3.68%	92.64%	-9.5	48.09	54.84%	-28.31%
AXSM	3.5B	270.6M	-0.50%	3.10%	-14.69	12.99	440.80%	-27.84%
ARWR	3.0B	240.7M	-7.87%	-39.98%	-10.07	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-5.69%	-19.43%	-45.92	3.87	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-1.57%	-9.52%	24.79	4.45	85.90%	-14.05%
NVAX	659.2M	983.7M	3.97%	-34.13%	-1.21	0.67	-50.36%	17.16%
CRBP	400.8M	881.7K	1.98%	349.41%	-8.99	466.16	-77.61%	-5.33%
INO	280.7M	4.9M	-3.22%	25.10%	-2.08	57.68	-54.97%	51.71%
IBIO	7.0M	2.1M	-29.72%	84.40%	-0.26	2.14	-13.45%	66.37%

VYNE Therapeutics Inc. News

Latest updates

VYNE Therapeutics Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-33.3%	76,000	114,000	135,000	99,000	6,000	167,000	126,000	178,000	273,000	133,000	295,000	2,290,500	4,286,000	3,269,000	11,688,000	1,750,000	135,000	-	-	308,000	154,000
Costs and Expenses	8.8%	6,907,500	6,348,000	10,453,000	5,974,000	7,990,000	9,500,000	8,413,000	8,869,000	9,118,500	10,900,000	9,837,000	9,987,000	25,741,000	26,389,000	178,649,000	41,368,000	37,566,000	23,199,000	19,359,000	16,192,000	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	21,931,000	17,426,000	17,216,000	19,669,000	18,440,000
S&GA Expenses	28.2%	3,885,000	3,030,000	3,220,000	3,240,000	3,711,000	3,954,000	4,305,000	4,417,000	4,795,000	4,983,000	4,789,000	5,732,000	17,903,000	19,766,000	26,459,000	25,415,000	22,220,000	10,747,000	6,803,000	5,344,000	5,191,000
R&D Expenses	-8.9%	3,022,500	3,318,000	7,233,000	2,734,000	4,279,000	5,546,000	4,108,000	4,452,000	4,323,500	5,917,000	5,048,000	4,255,000	7,838,000	6,623,000	13,119,000	15,953,000	15,346,000	12,452,000	12,556,000	10,848,000	26,561,000
EBITDA Margin	21.4%	-65.74	-83.60	-80.12	-77.37	-70.93	-46.72	-51.34	-43.02	-41.83	-8.76	-5.92	-13.89	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-10,000	3,474,000	1,074,000	1,062,000	1,161,000	1,092,000	1,070,000	1,067,000	632,000	289,000	-	-	-
Income Taxes	-	-	-	-	-	13,000	-	-	-	-448,000	-	-	-	-	1,000	-259,000	-	-	-	-	-176,000	-
Earnings Before Taxes	-1.3%	-6,151,500	-6,071,000	-10,038,000	-5,612,000	-7,748,000	-9,255,000	-8,235,000	-8,694,000	-8,819,500	-14,276,000	-10,685,000	-10,876,000	-23,181,000	-24,713,000	-167,699,000	-40,233,000	-37,820,000	-23,161,000	-18,993,000	-15,380,000	-
EBT Margin	21.0%	-65.74	-83.25	-80.23	-77.51	-71.14	-47.05	-56.37	-48.32	-47.97	-9.92	-6.34	-14.17	-	-	-	-	-	-	-	-	-
Net Income	6.0%	-6,188,000	-6,584,000	-10,058,000	-5,622,000	-9,945,000	-9,459,000	-8,476,000	4,670,000	-11,570,000	-21,285,000	-19,924,000	-20,550,000	-23,181,000	-24,714,000	-167,440,000	-40,233,000	-21,498,000	-23,161,000	-18,993,000	-15,204,000	-17,594,000
Net Income Margin	26.2%	-67.10	-90.99	-86.20	-84.18	-48.66	-33.38	-51.64	-54.73	-78.76	-14.28	-8.06	-14.76	-	-	-	-	-	-	-	-	-
Free Cashflow	0.3%	-5,137,000	-5,152,000	-9,574,000	-5,478,000	-4,811,000	-7,125,000	-8,225,000	-9,039,000	-10,018,000	-17,541,000	-16,257,000	-12,551,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	407.0%	98.00	19.00	25.00	35.00	41.00	47.00	55.00	64.00	67.00	81.00	134	149	94.00	108	131	161	81.00	97.00	114	126	140
Current Assets	448.0%	96.00	18.00	23.00	33.00	38.00	44.00	52.00	61.00	63.00	76.00	128	143	87.00	98.00	119	98.00	76.00	93.00	113	125	140
Cash Equivalents	98.2%	31.00	15.00	21.00	30.00	31.00	36.00	43.00	50.00	43.00	52.00	103	119	58.00	73.00	97.00	58.00	45.00	41.00	39.00	19.00	28.00
Inventory	-	-	-	-	-	-	-	-	-	7.00	8.00	8.00	8.00	7.00	7.00	6.00	3.00	1.00	-	-	-	-
Net PPE	-	-	-	-	-	-	0.00	0.00	0.00	0.00	0.00	1.00	1.00	1.00	3.00	3.00	3.00	3.00	0.00	0.00	0.00	0.00
Liabilities	15.3%	9.00	8.00	8.00	9.00	9.00	7.00	7.00	9.00	18.00	22.00	59.00	56.00	56.00	58.00	59.00	91.00	64.00	10.00	12.00	11.00	10.00
Current Liabilities	16.9%	8.00	6.00	6.00	8.00	9.00	-	-	-	18.00	21.00	58.00	22.00	22.00	23.00	24.00	57.00	29.00	9.00	12.00	11.00	10.00
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	33.00	33.00	33.00	33.00	33.00	33.00	-	-	-	-
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	33.00	33.00	33.00	33.00	33.00	33.00	-	-	-	-
Shareholder's Equity	671.3%	89.00	12.00	17.00	26.00	31.00	40.00	48.00	56.00	49.00	59.00	75.00	93.00	37.00	50.00	72.00	70.00	18.00	54.00	60.00	78.00	92.00
Retained Earnings	-0.9%	-691	-685	-678	-668	-662	-652	-643	-634	-639	-628	-606	-586	-566	-543	-518	-350	-310	-162	-145	-129	-110
Additional Paid-In Capital	12.0%	780	697	696	695	694	693	692	691	688	687	682	680	604	593	590	420	328	250	248	245	241
Shares Outstanding	326.6%	14.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	13.00	-	-	-	22.00	-	-	-	155	-	-	-	245	-	-	-	101	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	0.3%	-5,137	-5,152	-9,552	-5,500	-4,811	-7,125	-8,225	-9,039	-10,018	-17,541	-16,257	-12,551	-25,375	-23,637	-35,859	-52,211	-22,246	-21,787	-12,719	-16,642	-32,548
Share Based Compensation	-17.7%	710	863	876	856	1,067	1,174	1,163	893	1,332	2,405	1,901	2,442	2,953	2,620	10,768	1,759	1,289	1,269	1,387	950	2,756
Cashflow From Investing	-Infinity%	-62,354	-	-	5,000	1.00	-86.00	-	15,752	-	-	1,027	-	2,002	-	21,125	65,980	6,034	-4,677	32,773	7,739	18,050
Cashflow From Financing	175978.7%	82,663	-47.00	-5.00	-217	208	-26.00	-61.00	1,532	-38.00	-33,559	-129	73,503	7,980	82.00	53,606	140	19,996	27,936	2.00	16.00	-33,537

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VYNE Income Statement

2023-12-31

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Total Revenues	$ 424	$ 477
Operating Expenses:
Research and development	16,307	18,385
General and administrative	13,375	16,387
Total Operating Expenses	29,682	34,772
Operating Loss	(29,258)	(34,295)
Other income, net	1,386	363
Loss from continuing operations before income taxes	(27,872)	(33,932)
Income tax expense	0	13
Loss from continuing operations	(27,872)	(33,945)
(Loss) income from discontinued operations, net of income taxes	(580)	10,735
Net Loss	$ (28,452)	$ (23,210)
Loss per share from continuing operations, basic (in dollars per share)	$ (2.72)	$ (10.65)
Loss per share from continuing operations, diluted (in dollars per share)	(2.72)	(10.65)
(Loss) income per share from discontinuing operations, basic (in dollars per share)	(0.06)	3.37
(Loss) income per share from discontinuing operations, diluted (in dollars per share)	(0.06)	3.37
Loss per share basic (in dollars per share)	(2.78)	(7.28)
Loss per share diluted (in dollars per share)	$ (2.78)	$ (7.28)
Weighted average shares outstanding - basic (in shares)	10,273	3,186
Weighted average shares outstanding - diluted (in shares)	10,273	3,186
Other comprehensive income:
Unrealized gain on marketable securities, net of tax of $0	$ 26	$ 0
Total other comprehensive income	26	0
Comprehensive loss	$ (28,426)	$ (23,210)

VYNE Balance Sheet

2023-12-31

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 30,620,000	$ 30,908,000
Restricted cash	54,000	67,000
Investment in marketable securities (Note 6)	62,633,000	0
Amount due from sale of MST Franchise	0	5,000,000
Prepaid and other current assets	2,656,000	2,300,000
Total Current Assets	95,963,000	38,275,000
Non-current Assets:
Operating lease right of use assets (Note 9)	207,000	0
Non-current prepaid expenses and other assets	1,515,000	2,483,000
Total Non-current Assets	1,722,000	2,483,000
Total Assets	97,685,000	40,758,000
Current Liabilities:
Trade payables	1,659,000	2,386,000
Accrued expenses (Note 8)	4,119,000	4,381,000
Employee-related obligations	1,645,000	2,372,000
Liability for employee severance benefits	0	206,000
Operating lease liabilities (Note 9)	115,000	0
Total Current Liabilities	7,538,000	9,345,000
Long-term Liabilities:
Non-current operating lease liabilities (Note 9)	99,000	0
Other liabilities	1,313,000	0
Total Long-term Liabilities	1,412,000	0
Total Liabilities	8,950,000	9,345,000
Commitments and Contingencies (Note 11)
Mezzanine Equity:
Convertible Preferred Stock: $0.0001 par value; 20,000,000 shares authorized at December 31, 2023 and December 31, 2022; Series A Preferred Stock: 0 and 3,000 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively (Note 12)	0	211,000
Shareholders' Equity:
Preferred stock: $0.0001 par value; 20,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; no shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	0	0
Common stock: $0.0001 par value; 150,000,000 shares authorized at December 31, 2023 and December 31, 2022; 14,098,888 and 3,229,704 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	1,000	0
Additional paid-in capital	780,044,000	693,937,000
Accumulated other comprehensive income	26,000	0
Accumulated deficit	(691,336,000)	(662,735,000)
Total Shareholders' Equity	88,735,000	31,202,000
Total Liabilities, Mezzanine Equity and Shareholders’ Equity	$ 97,685,000	$ 40,758,000

About VYNE Therapeutics Inc.

VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor for the treatment of immuno-inflammatory indications; and FMX114, a combination gel formation of tofacitinib and fingolimod, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.

CEO	Mr. David T. Domzalski
WEBSITE	vynetherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	12

VYNE Therapeutics Inc. Frequently Asked Questions

What is the ticker symbol for VYNE Therapeutics Inc.? What does VYNE stand for in stocks?

VYNE is the stock ticker symbol of VYNE Therapeutics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of VYNE Therapeutics Inc. (VYNE)?

As of Thu May 02 2024, market cap of VYNE Therapeutics Inc. is 34.97 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VYNE stock?

You can check VYNE's fair value in chart for subscribers.

What is the fair value of VYNE stock?

You can check VYNE's fair value in chart for subscribers. The fair value of VYNE Therapeutics Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of VYNE Therapeutics Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VYNE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is VYNE Therapeutics Inc. a good stock to buy?

The fair value guage provides a quick view whether VYNE is over valued or under valued. Whether VYNE Therapeutics Inc. is cheap or expensive depends on the assumptions which impact VYNE Therapeutics Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VYNE.

What is VYNE Therapeutics Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 02 2024, VYNE's PE ratio (Price to Earnings) is -1.23 and Price to Sales (PS) ratio is 82.47. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VYNE PE ratio will change depending on the future growth rate expectations of investors.